Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

@article{AppelDingemanse1999IntegratedMO,
  title={Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.},
  author={Silke Appel-Dingemanse and M O Lemarechal and A Kumle and Martine Hubert and Eric Legangneux},
  journal={British journal of clinical pharmacology},
  year={1999},
  volume={47 5},
  pages={483-91}
}
AIMS The purpose of the present study was to assess the pharmacokinetics of the novel selective 5-HT4 receptor agonist SDZ HTF 919 (HTF) including food effect, absolute bioavailability, interoccasion and intersubject variabilities. METHODS In the randomized, open-label, three treatment, four period crossover study, HTF was administered to 12 young healthy male subjects as a 12 mg tablet (twice under fasted and once under fed conditions) and a 3 mg intravenous (i.v.) infusion over 40 min… CONTINUE READING